These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30878589)

  • 1. Rapid sample-saving biophysical characterisation and long-term storage stability of liquid interferon alpha2a formulations: Is there a correlation?
    Svilenov H; Winter G
    Int J Pharm; 2019 May; 562():42-50. PubMed ID: 30878589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ReFOLD assay for protein formulation studies and prediction of protein aggregation during long-term storage.
    Svilenov H; Winter G
    Eur J Pharm Biopharm; 2019 Apr; 137():131-139. PubMed ID: 30818009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancing Therapeutic Protein Discovery and Development through Comprehensive Computational and Biophysical Characterization.
    Gentiluomo L; Svilenov HL; Augustijn D; El Bialy I; Greco ML; Kulakova A; Indrakumar S; Mahapatra S; Morales MM; Pohl C; Roche A; Tosstorff A; Curtis R; Derrick JP; Nørgaard A; Khan TA; Peters GHJ; Pluen A; Rinnan Å; Streicher WW; van der Walle CF; Uddin S; Winter G; Roessner D; Harris P; Frieß W
    Mol Pharm; 2020 Feb; 17(2):426-440. PubMed ID: 31790599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orthogonal Techniques to Study the Effect of pH, Sucrose, and Arginine Salts on Monoclonal Antibody Physical Stability and Aggregation During Long-Term Storage.
    Svilenov HL; Kulakova A; Zalar M; Golovanov AP; Harris P; Winter G
    J Pharm Sci; 2020 Jan; 109(1):584-594. PubMed ID: 31689429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulations That Suppress Aggregation During Long-Term Storage of a Bispecific Antibody are Characterized by High Refoldability and Colloidal Stability.
    Svilenov HL; Winter G
    J Pharm Sci; 2020 Jun; 109(6):2048-2058. PubMed ID: 32194093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term stabilization of a new freeze-dried and albumin-free formulation of recombinant human interferon alpha 2b.
    Ruiz L; Reyes N; Sotolongo J; Aroche K; Aldana R; Báez R; Hardy E
    PDA J Pharm Sci Technol; 2006; 60(1):72-8. PubMed ID: 17089680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basal buffer systems for a newly glycosylated recombinant human interferon-β with biophysical stability and DoE approaches.
    Kim NA; Song K; Lim DG; Hada S; Shin YK; Shin S; Jeong SH
    Eur J Pharm Sci; 2015 Oct; 78():177-89. PubMed ID: 26215462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microcalorimetric studies of the effects on the interactions of human recombinant interferon-alpha2a.
    Huang SL; Lin FY; Yang CP
    Eur J Pharm Sci; 2005 Apr; 24(5):545-52. PubMed ID: 15784344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrasonic rheology of a monoclonal antibody (IgG2) solution: implications for physical stability of proteins in high concentration formulations.
    Saluja A; Badkar AV; Zeng DL; Kalonia DS
    J Pharm Sci; 2007 Dec; 96(12):3181-95. PubMed ID: 17588261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of stable liquid formulations for adenovirus-based vaccines.
    Evans RK; Nawrocki DK; Isopi LA; Williams DM; Casimiro DR; Chin S; Chen M; Zhu DM; Shiver JW; Volkin DB
    J Pharm Sci; 2004 Oct; 93(10):2458-75. PubMed ID: 15349956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-throughput screening and stability optimization of anti-streptavidin IgG1 and IgG2 formulations.
    Alekseychyk L; Su C; Becker GW; Treuheit MJ; Razinkov VI
    J Biomol Screen; 2014 Oct; 19(9):1290-301. PubMed ID: 25023322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective statistical analysis of lyophilized protein formulations of progenipoietin using PLS: determination of the critical parameters for long-term storage stability.
    Katayama DS; Kirchhoff CF; Elliott CM; Johnson RE; Borgmeyer J; Thiele BR; Zeng DL; Qi H; Ludwig JD; Manning MC
    J Pharm Sci; 2004 Oct; 93(10):2609-23. PubMed ID: 15349970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stability of buffer-free freeze-dried formulations: A feasibility study of a monoclonal antibody at high protein concentrations.
    Garidel P; Pevestorf B; Bahrenburg S
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):125-39. PubMed ID: 26455339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody.
    Cleland JL; Lam X; Kendrick B; Yang J; Yang TH; Overcashier D; Brooks D; Hsu C; Carpenter JF
    J Pharm Sci; 2001 Mar; 90(3):310-21. PubMed ID: 11170024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based discovery of a new protein-aggregation breaking excipient.
    Tosstorff A; Svilenov H; Peters GHJ; Harris P; Winter G
    Eur J Pharm Biopharm; 2019 Nov; 144():207-216. PubMed ID: 31521717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-buffering antibody formulations.
    Gokarn YR; Kras E; Nodgaard C; Dharmavaram V; Fesinmeyer RM; Hultgen H; Brych S; Remmele RL; Brems DN; Hershenson S
    J Pharm Sci; 2008 Aug; 97(8):3051-66. PubMed ID: 18023013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting accelerated aggregation rates for monoclonal antibody formulations, and challenges for low-temperature predictions.
    Brummitt RK; Nesta DP; Roberts CJ
    J Pharm Sci; 2011 Oct; 100(10):4234-43. PubMed ID: 21671226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein Aggregation in Frozen Trehalose Formulations: Effects of Composition, Cooling Rate, and Storage Temperature.
    Connolly BD; Le L; Patapoff TW; Cromwell MEM; Moore JMR; Lam P
    J Pharm Sci; 2015 Dec; 104(12):4170-4184. PubMed ID: 26398200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability Studies of a Freeze-Dried Recombinant Human Epidermal Growth Factor Formulation for Wound Healing.
    Santana H; García G; Vega M; Beldarraín A; Páez R
    PDA J Pharm Sci Technol; 2015; 69(3):399-416. PubMed ID: 26048746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of formulation robustness for nano-crystalline suspensions using failure mode analysis or derisking approach.
    Nakach M; Authelin JR; Voignier C; Tadros T; Galet L; Chamayou A
    Int J Pharm; 2016 Jun; 506(1-2):320-31. PubMed ID: 27102992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.